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Unfortunately, the original version of this article [1] con-
tained an error. The original article was published con-
taining two incorrect sentences.
This sentence appeared in the abstract as follows “A
significant difference was observed between patients
who had taken PPI and who not with ORR (46.9 vs.
67.7 %, p = 0.049) and median TTP (9.7 months vs.
8.7 months, p = 0.045).” This should have read as “A sig-
nificant difference was observed between patients who
had taken PPI and who not with ORR (67.7 vs. 46.9 %,
p = 0.049) and median TTP (9.7 months vs. 8.7 months,
p = 0.045).”
The following sentence which appeared in the main
text was also incorrect. In the original article it read as
“As planned, we compared the pool of patients receiving
PPI to those treated exclusively with chemotherapy and
the statistical analysis showed a significant difference in
term of ORR between patients who received PPI, as
compared to those treated with chemotherapy alone
(46.9 vs. 67.7 %, p = 0.049).” However this should have
read as “As planned, we compared the pool of patients
receiving PPI to those treated exclusively with chemo-
therapy and the statistical analysis showed a significant
difference in term of ORR between patients who re-
ceived PPI, as compared to those treated with chemo-
therapy alone (67.7 vs. 46.9 %, p = 0.049).”
Both sentences have now been corrected in the ori-
ginal article. The author apologizes for any inconveni-
ence caused.
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